New Strain of Covid – Cicada Variant Symptoms, UK Status

A newly identified COVID-19 variant known as BA.3.2, nicknamed “Cicada,” has drawn attention from health monitoring systems worldwide. First detected in late 2024, this Omicron subvariant carries distinctive mutations that set it apart from earlier strains, though current evidence suggests it does not cause more severe illness than its predecessors. Health authorities continue tracking its spread while emphasising that existing vaccines and testing methods remain effective tools against it.

The variant derives its informal name from a behaviour pattern reminiscent of cicada insects—appearing to fade before resurfacing in new locations. As of early 2026, COVID-19 has settled into a recognisable seasonal rhythm, with BA.3.2 appearing in monitoring reports alongside other circulating subvariants. Understanding its symptoms, transmission patterns, and how it compares to previous strains can help individuals make informed decisions about their health and testing choices.

Public health agencies including the World Health Organization and the United States Centers for Disease Control and Prevention continue surveillance efforts, though specific data from UK authorities remains limited in publicly available reports. This article provides a comprehensive overview based on verified information from recognised medical and health sources.

What are the symptoms of the new strain of COVID?

Symptoms associated with the BA.3.2 variant closely mirror those of other recent Omicron subvariants, presenting primarily as a respiratory illness similar to the common cold. No new or unusual symptom patterns have been documented in the available medical literature. Standard COVID-19 tests continue to detect the variant effectively, and negative test results in individuals displaying symptoms typically indicate an alternate illness.

Most commonly reported symptoms

The most frequently reported symptoms align with typical upper respiratory infections. According to sources including NYU Langone and Stony Brook Medicine, the predominant symptoms include fever or chills, persistent cough, general fatigue, and sore throat. Nasal congestion, sneezing, and headaches also rank among the most common presentations. These symptoms generally appear within two to fourteen days of exposure and resolve within one to two weeks in uncomplicated cases.

• Fever or chills
• Cough
• Fatigue and weakness
• Sore throat
• Runny or stuffy nose
• Headache
• Sneezing

Additional symptoms to note

Beyond the most common symptoms, some individuals have reported experiencing shortness of breath, muscle or body aches, and gastrointestinal symptoms such as nausea, vomiting, or diarrhoea. Neurological symptoms including brain fog and difficulty concentrating have also been documented, though these tend to occur less frequently. A reduced appetite and temporary loss of taste or smell remain possible but are now considered less common than during earlier phases of the pandemic.

What is the new COVID Cicada variant?

The BA.3.2 variant earned the informal nickname “Cicada” due to its distinctive behavioural pattern—seemingly disappearing from monitoring systems before reemerging in new geographic areas. This characteristic mirrors the life cycle of cicada insects, which spend extended periods underground before appearing in large numbers. The variant belongs to the broader Omicron family and represents one of numerous sub-lineages that have evolved since the initial Omicron identification in late 2021.

Origin and genetic characteristics

Scientists believe the variant may have emerged sometime between December 2023 and July 2024, though precise dating remains challenging due to inconsistent genomic surveillance in some regions. The first confirmed identification occurred in South Africa during November 2024. What distinguishes BA.3.2 from its relatives is its substantial genetic divergence: the variant carries over 70 mutations compared to the original Wuhan strain, with more than 50 of these located in the spike protein alone.

This significant mutational profile raised initial concerns about potential increased transmissibility and the possibility of partial immune evasion. However, Gavi, the Vaccine Alliance notes that current vaccines remain effective at preventing severe disease, hospitalisation, and death even when they may not completely prevent infection.

Global spread and current circulation

The variant has been detected across multiple continents, with documented cases in the United States, South Africa, and numerous other countries. Wastewater monitoring in the United States has identified genetic signatures consistent with BA.3.2 in 25 states, suggesting wider circulation than confirmed case counts indicate. According to World Health Organization data, BA.3.2 accounts for approximately 8 percent of variants tracked globally.

Despite its spread, BA.3.2 represents a relatively small proportion of total COVID-19 cases in most regions. In the United States, the CDC estimates the variant accounts for approximately 0.19 percent of cases. Health authorities have classified it as a variant under monitoring rather than a variant of concern, indicating that while surveillance continues, no urgent public health action is required at this stage.

Is there a new strain of COVID in the UK?

Publicly available reports from UK health authorities do not contain specific case counts or detailed surveillance data for the BA.3.2 variant within the United Kingdom. The UK Health Security Agency (UKHSA) continues monitoring COVID-19 variants through routine genomic surveillance, though recent published reports have focused primarily on other sub-lineages including XFG and NB.1.8.1.

The absence of specific UK data does not indicate that the variant is absent from the country. Limited genomic sequencing coverage globally means that variant distribution data may be incomplete. International travel and ongoing community transmission virtually ensure that variants circulating internationally eventually reach the UK, though timing and prevalence vary.

UK monitoring context

According to UKHSA blog posts from September 2025, health officials maintain active surveillance of circulating variants without identifying immediate cause for concern regarding the current variant landscape. The European Centre for Disease Prevention and Control also tracks variant circulation across member states, though their publicly reported assessments have not highlighted specific BA.3.2 data for the UK.

For individuals in the UK, the practical guidance remains consistent regardless of the specific variant in circulation. Vaccination remains the most effective protection against severe COVID-19 outcomes, with updated formulations including the 2025–2026 LP.8.1-adapted mRNA vaccines providing strong protection against current variants.

How long does the new strain of COVID last?

Definitive data specifically addressing the duration of illness caused by BA.3.2 remains limited. Based on the similarity of symptoms to other recent Omicron subvariants, health experts anticipate that the illness course follows comparable patterns. Most individuals with mild to moderate symptoms can expect recovery within one to two weeks, while more severe cases or complications may extend recovery time significantly.

Several factors influence the duration and severity of any COVID-19 variant infection, including vaccination status, prior infection history, age, and underlying health conditions. Individuals who are immunocompromised or have significant comorbidities may experience prolonged symptoms and slower recovery regardless of the specific variant causing infection.

Recovery factors

For most people, acute symptoms such as fever, cough, and fatigue resolve within seven to ten days. Some individuals report persistent cough or fatigue for several weeks after initial recovery, a phenomenon sometimes referred to as post-viral syndrome. Signs COVID Is Getting Better – Timeline, Relapse & Recovery Tips provides detailed guidance on tracking recovery progress and recognising when symptoms are resolving.

The CDC’s Morbidity and Mortality Weekly Report from early 2026 indicates that updated vaccines continue providing robust protection against severe disease even with variant evolution. This suggests that vaccinated individuals who do contract BA.3.2 typically experience milder symptoms and shorter illness duration compared to unvaccinated individuals.

• Mild cases: Most symptoms resolve within 7–14 days
• Moderate cases: Full recovery typically within 2–4 weeks
• Severe cases: Recovery may extend to 6 weeks or longer
• Post-viral symptoms: Fatigue or cough may persist for several weeks

How has the variant evolved over time?

Understanding the timeline of BA.3.2’s emergence provides context for its current position in the broader COVID-19 landscape. While precise dating remains challenging due to gaps in global surveillance, available evidence suggests a gradual international spread that accelerated through late 2024 and early 2025.

1. Late 2023 to mid-2024: Estimated period of initial emergence based on genetic divergence analysis
2. November 2024: First confirmed identification in South Africa
3. Early 2025: Detection in multiple countries, including United States
4. April 2025: WHO data indicates approximately 8% global variant proportion
5. September 2025: UKHSA reports on current variant monitoring without specific BA.3.2 concerns
6. April 2026: BA.3.2 noted in monitoring reports alongside other circulating variants

The variant has not replaced other dominant strains during the 2024–2026 period, instead circulating alongside them without causing the dramatic waves associated with earlier Omicron subvariants. April 2026 reports from health monitoring services indicate that COVID-19 has settled into a predictable seasonal pattern, with multiple variants circulating simultaneously at relatively low levels.

What is confirmed versus what remains unclear?

Transparency about what science has established versus what remains under investigation helps readers understand the limitations of current knowledge. The following comparison outlines confirmed information alongside areas where uncertainty persists.

Why does COVID-19 tracking matter?

Ongoing variant surveillance serves multiple important public health functions. By tracking which variants circulate and how they change over time, health authorities can anticipate potential surges, allocate healthcare resources appropriately, and update vaccine recommendations when necessary. The global sharing of genomic data through systems coordinated by WHO and national health agencies enables rapid response to genuinely concerning developments.

The COVID-19 landscape has evolved considerably since the pandemic’s early stages. As population immunity has built through vaccination and repeated infection, the virus has settled into a pattern more similar to seasonal influenza. AARP reports confirm that current variants, including BA.3.2, typically cause milder illness in most vaccinated individuals while remaining potentially serious for older adults and those with underlying health conditions.

Variant monitoring also informs vaccine development. The updated 2025–2026 LP.8.1-adapted mRNA vaccines incorporate knowledge gained from tracking variant evolution, providing broader protection against emerging sub-lineages. This adaptive approach represents the long-term strategy for managing COVID-19 alongside seasonal vaccination programmes for vulnerable populations.

What are experts saying about the current situation?

Medical professionals have largely characterised the current variant landscape as manageable rather than alarming. Reports from Hematology Advisor indicate that clinical observations through early 2026 show no significant deviation from established patterns, with symptoms remaining recognisable and testable through standard methods.

“So far, symptoms appear similar to those reported with other recent Omicron subvariants. The variant is being monitored, but there is no indication of increased severity or unusual clinical presentations.”

— Medical reporting from Hematology Advisor, April 2026

“Current vaccines remain effective against severe disease even with the variant’s mutations. The public health risk assessment remains low based on available evidence.”

— Gavi, the Vaccine Alliance summary on BA.3.2

Stony Brook Medicine emphasises that while the mutation profile of BA.3.2 warrants continued monitoring, individuals should focus on proven protective measures: staying up to date with vaccinations, testing when symptomatic, and seeking medical care if symptoms worsen significantly. The absence of alarm does not mean complacency, particularly for those at higher risk of severe outcomes.

Summary: What you need to know about the new COVID strain

The BA.3.2 variant, nicknamed “Cicada,” represents one of several Omicron subvariants currently circulating globally. It has been detected in the United States, South Africa, and other countries, accounting for approximately 8 percent of tracked variants according to WHO data. Symptoms match those of other recent subvariants—primarily respiratory symptoms resembling a common cold—and standard COVID-19 tests detect it effectively. Health authorities have assessed its additional public health risk as low, with no evidence of increased severity compared to other circulating variants.

Vaccines continue providing strong protection against severe disease, hospitalisation, and death. Specific data on UK prevalence remains limited in publicly available reports, though monitoring continues through UKHSA and European surveillance systems. For most healthy, vaccinated individuals, infection results in mild to moderate illness resolving within one to two weeks. What Causes Type 2 Diabetes – Science Explained provides context on how underlying health conditions can affect recovery from respiratory infections more broadly.

As COVID-19 continues its transition toward an endemic seasonal pattern, variant monitoring remains an important but routine aspect of public health surveillance. Individuals are encouraged to follow current vaccination recommendations, test when symptomatic, and consult healthcare providers if symptoms persist or worsen significantly.

Frequently asked questions